Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential maps

Abstract17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the last step of the estrogen biosynthesis, namely the reduction of estrone to the biologically potent estradiol. As such it is a potentially attractive drug target for the treatment of estrogen-dependent diseases like breast cancer and endometriosis. 17β-HSD1 belongs to the bisubstrate enzymes and exists as an ensemble of conformations. These principally differ in the region of the βFαG′-loop, suggesting a prominent role in substrate and inhibitor binding. Although several classes of potent non-steroidal 17β-HSD1 inhibitors currently exist, their binding mode is still unclear. We aimed to elucidate the binding mode of bis(hydroxyphenyl)arenes, a highly potent class of 17β-HSD1 inhibitors, and to rank these compounds correctly with respect to their inhibitory potency, two essential aspects in drug design. Ensemble docking experiments resulted in a steroidal binding mode for the closed enzyme conformations and in an alternative mode for the opened and occluded conformers with the inhibitors placed below the NADPH interacting with it synergically via π–π stacking and H-bond formation. Both binding modes were investigated by MD simulations and MM-PBSA binding free energy estimations using as representative member for this class compound 1 (50 nM). Notably, only the alternative binding mode proved stable and was energetically more favorable, while when simulated in the steroidal binding mode compound 1 was displaced from the active site. In parallel, ab initio studies of small NADPH-inhibitor complexes were performed, which supported the importance of the synergistic interaction between inhibitors and cofactor.

[1]  J. Brosens,et al.  Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. , 2010, The American journal of pathology.

[2]  Janet M Thornton,et al.  The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. , 2009, Chemico-biological interactions.

[3]  N. J. Bush Advances in hormonal therapy for breast cancer. , 2007, Seminars in oncology nursing.

[4]  R. Hartmann,et al.  6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2. , 2000, European journal of medicinal chemistry.

[5]  M. Negri,et al.  Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). , 2008, Journal of medicinal chemistry.

[6]  W. Kohn,et al.  Self-Consistent Equations Including Exchange and Correlation Effects , 1965 .

[7]  G. Rastelli,et al.  Assessing Protein Kinase Selectivity with Molecular Dynamics and MM‐PBSA Binding Free Energy Calculations , 2011, Chemical biology & drug design.

[8]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[9]  G. Scuseria,et al.  Gaussian 03, Revision E.01. , 2007 .

[10]  Y. Tremblay,et al.  Androgenic and estrogenic 17β-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  H. Tutill,et al.  Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.

[12]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[13]  V. Adamo,et al.  Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Zupan,et al.  REPRESENTATION OF MOLECULAR ELECTROSTATIC POTENTIALS BY TOPOLOGICAL FEATURE MAPS , 1994 .

[15]  R. Hartmann,et al.  Development of a biological screening system for the evaluation of highly active and selective 17β-HSD1-inhibitors as potential therapeutic agents , 2009, Molecular and Cellular Endocrinology.

[16]  T. Halgren MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.

[17]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[18]  J. Adamski,et al.  Recent advances in 17beta-hydroxysteroid dehydrogenases , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  R. Hartmann,et al.  Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. , 2008, Journal of medicinal chemistry.

[20]  Michael Feig,et al.  MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. , 2004, Journal of molecular graphics & modelling.

[21]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[22]  P A Komesaroff,et al.  Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[24]  R. Hartmann,et al.  Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. , 2010, Journal of medicinal chemistry.

[25]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[26]  M. Negri,et al.  New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. , 2009, Journal of medicinal chemistry.

[27]  Giulio Rastelli,et al.  Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..

[28]  Takashi Suzuki,et al.  In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology , 2009, Pathology international.

[29]  R. Hartmann,et al.  Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. , 2008, Bioorganic & medicinal chemistry.

[30]  J. D. Doll,et al.  Generalized Langevin equation approach for atom/solid-surface scattering: General formulation for classical scattering off harmonic solids , 1976 .

[31]  B. Husen,et al.  New inhibitors of 17β-hydroxysteroid dehydrogenase type 1 , 2006, Molecular and Cellular Endocrinology.

[32]  Y. Miyoshi,et al.  Involvement of up‐regulation of 17β‐hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers , 2001, International journal of cancer.

[33]  M. Poutanen,et al.  Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme , 2006, Molecular and Cellular Endocrinology.

[34]  H. Sasano,et al.  7β-hydroxysteroid Dehydrogenase Type 1 and Type 2 in Human Breast Carcinoma: a Correlation to Clinicopathological Parameters , 2022 .

[35]  A. Becke Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[36]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[37]  Andrew L. Lee,et al.  Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state. , 2009, Structure.

[38]  O. Stål,et al.  Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. , 2001, Cancer research.

[39]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[40]  A. Romano,et al.  Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. , 2009, The Journal of clinical endocrinology and metabolism.

[41]  A. Jansson 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  M. Negri,et al.  Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. , 2010, Bioorganic & medicinal chemistry.

[43]  T. Key,et al.  Oestrogen exposure and breast cancer risk , 2003, Breast Cancer Research.

[44]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[45]  H. Tutill,et al.  Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. , 2008, Bioorganic & medicinal chemistry.

[46]  J. Bartlett,et al.  Hormonal therapy for postmenopausal breast cancer: the science of sequencing , 2007, Breast Cancer Research and Treatment.

[47]  R. Hartmann,et al.  Structure–activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors , 2009, Molecular and Cellular Endocrinology.

[48]  M. Poutanen,et al.  In vivo mouse model for analysis of hydroxysteroid (17β) dehydrogenase 1 inhibitors , 2009, Molecular and Cellular Endocrinology.

[49]  David L Mobley,et al.  The Confine-and-Release Method: Obtaining Correct Binding Free Energies in the Presence of Protein Conformational Change. , 2007, Journal of chemical theory and computation.

[50]  Fernand Labrie,et al.  The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology , 1997, Steroids.

[51]  Sheng-Xiang Lin,et al.  Human estrogenic 17beta-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. , 1999, Biochemical and biophysical research communications.

[52]  R. Hartmann,et al.  The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-Hydroxysteroid Dehydrogenase (17β-HSD) type 1 and type 2 , 2009, Molecular and Cellular Endocrinology.

[53]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[54]  M. Recanatini,et al.  Insights in 17β-HSD1 Enzyme Kinetics and Ligand Binding by Dynamic Motion Investigation , 2010, PloS one.

[55]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[56]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[57]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[58]  T. Darden,et al.  Molecular dynamics simulations of biomolecules: long-range electrostatic effects. , 1999, Annual review of biophysics and biomolecular structure.

[59]  G. Hodgen,et al.  Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression. , 1980, Fertility and sterility.

[60]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[61]  F. Grodstein,et al.  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.

[62]  Takashi Suzuki,et al.  17β‐Hydroxysteroid Dehydrogenases in Human Breast Cancer , 2009, Annals of the New York Academy of Sciences.

[63]  R. Hartmann,et al.  Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. , 2008, Journal of medicinal chemistry.

[64]  B. Potter,et al.  17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer , 2008 .

[65]  S. Gobec,et al.  Inhibitors of 17-Hydroxysteroid Dehydrogenase Type 1 , 2008 .

[66]  O. Stål,et al.  17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer , 2005, British Journal of Cancer.

[67]  D. Poirier Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. , 2009, Anti-cancer agents in medicinal chemistry.

[68]  Annamaria Lilienkampf,et al.  Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core. , 2009, Journal of medicinal chemistry.

[69]  P. Hohenberg,et al.  Inhomogeneous Electron Gas , 1964 .

[70]  T Darden,et al.  New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. , 1999, Structure.

[71]  J. Simard,et al.  Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. , 2000, Journal of molecular endocrinology.